Condition

Neuroendocrine Tumors

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 66 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials66

Recruiting18

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Sapu003 in Advanced mTOR-sensitive Solid TumorsNCT07369505 · 2025-12-15

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NENNCT06735560 · 2025-11-04

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsNCT04119024 · 2025-10-07

18F Labeled FAP Targeted Molecular Probe in Early Tumor DiagnosisNCT06937112 · 2025-04-10

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitNCT06805825 · 2025-02-03

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid TumorsNCT06505824 · 2024-08-02

Agnostic Therapy in Rare Solid TumorsNCT06638931 · 2024-07-16

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine TumorsNCT06472388 · 2024-04-24

Clinical Application of the J-PET Scanner PrototypeNCT06242119 · 2024-03-07

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.NCT05918302 · 2023-10-27

F-Tryptophan PET/CT in Human CancersNCT05556473 · 2022-09-29

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesNCT05000294 · 2021-12-07

18F-DOPA II - PET Imaging OptimizationNCT04706910 · 2021-01-20

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine DepartmentNCT04104529 · 2019-10-28

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerNCT03412877 · 2018-09-06

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryNCT03452774 · 2018-01-01

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaNCT03206060 · 2017-10-10

Integrated Cancer Repository for Cancer ResearchNCT02012699 · 2013-11-01

CardioNETPOL National Registry of Carcinoid Heart DiseaseNCT07450287 · 2026-06-01

NOT_YET_RECRUITING

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine TumorsNCT06764368 · 2025-01-01

NOT_YET_RECRUITING

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesNCT06577987 · 2024-08-14

ACTIVE_NOT_RECRUITING

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDGNCT05160480 · 2024-06-07

ENROLLING_BY_INVITATION

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent TumorsNCT04889742 · 2024-05-10

NOT_YET_RECRUITING

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsNCT06148636 · 2023-11-10

ACTIVE_NOT_RECRUITING

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsNCT05997056 · 2023-10-20

Observational Study on GEP-and Pulm-NET Treated at FPGNCT06402695 · 2023-09-15

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsNCT04915144 · 2023-01-15

Dual-Tracer Theranostic PETNCT05680675 · 2022-12-08

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer PatientsNCT05396118 · 2022-05-18

Neuroendocrine Tumors - Patient Reported OutcomesNCT05064150 · 2022-05-10

ACTIVE_NOT_RECRUITING

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesNCT05199272 · 2021-12-29

ACTIVE_NOT_RECRUITING

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerNCT04848337 · 2021-05-25

ACTIVE_NOT_RECRUITING

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315 · 2021-05-24

The Registry of Oncology Outcomes Associated With Testing and TreatmentNCT04028479 · 2021-05-05

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsNCT04579757 · 2021-03-05

Registry on NEN Patients and COVID-19NCT04444401 · 2020-06-15

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.NCT04276597 · 2020-03-04

Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingNCT04017104 · 2019-11-01

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)NCT05268952 · 2019-05-27

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.NCT03910660 · 2019-02-12

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerNCT03728361 · 2018-12-31

Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsNCT03600233 · 2018-12-15

ACTIVE_NOT_RECRUITING

A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic SystemNCT03670030 · 2018-11-05

DOTATOC PET/CT for Imaging NET PatientsNCT03583528 · 2018-07-11

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA TreatmentNCT05255133 · 2017-10-09

18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyNCT03042416 · 2017-06-29

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginNCT03095274 · 2017-04-11

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385 · 2017-03-17

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersNCT02936323 · 2016-12-08

The MetNET-2 TrialNCT02823691 · 2016-04-01

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)NCT02568267 · 2015-11-19

ACTIVE_NOT_RECRUITING

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)NCT02489903 · 2015-06-01

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.NCT01931488 · 2013-08-01

Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine TumorsNCT01755182 · 2013-07-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesNCT01794793 · 2013-06-10

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine TumorsNCT01719861 · 2012-10-01

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)NCT01524783 · 2012-03-30

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid TumorsNCT01970540 · 2011-05-25

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationNCT01317615 · 2011-04-01

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)NCT01253161 · 2011-02-01

Common interventions

Leading sponsors

British Columbia Cancer Agency 3 Hoffmann-La Roche 3 Grupo Espanol de Tumores Neuroendocrinos 2 National Cancer Institute (NCI) 2 Novartis Pharmaceuticals 2 Tel-Aviv Sourasky Medical Center 2 University of Alberta 2 23andMe, Inc. 1 Aadi Bioscience, Inc. 1 AC Camargo Cancer Center 1 Anusha Kalbasi 1 Barbara Ann Karmanos Cancer Institute 1 Beijing Chest Hospital 1 Bennett Chin 1 BioXcel Therapeutics Inc 1

Trial status mix

COMPLETED19

RECRUITING18

UNKNOWN9

ACTIVE_NOT_RECRUITING8

TERMINATED6

NOT_YET_RECRUITING3

WITHDRAWN2

ENROLLING_BY_INVITATION1

Phase mix

PHASE229

PHASE116

NA5

PHASE35

EARLY_PHASE12

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.